Spark Therapeutics, Inc. (NASDAQ:ONCE) – Analysts at William Blair issued their Q1 2018 earnings estimates for Spark Therapeutics in a report released on Tuesday. William Blair analyst R. Prasad anticipates that the biotechnology company will post earnings of ($1.99) per share for the quarter. William Blair currently has a “Outperform” rating on the stock. William Blair also issued estimates for Spark Therapeutics’ Q2 2018 earnings at ($1.73) EPS, Q3 2018 earnings at ($1.09) EPS, Q4 2018 earnings at ($1.22) EPS and FY2018 earnings at ($6.02) EPS.

Spark Therapeutics (NASDAQ:ONCE) last announced its earnings results on Wednesday, August 2nd. The biotechnology company reported ($1.89) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.75) by ($0.14). Spark Therapeutics had a negative return on equity of 59.74% and a negative net margin of 962.72%. The business had revenue of $1.48 million during the quarter, compared to analysts’ expectations of $1.33 million. During the same quarter in the previous year, the firm earned ($1.04) EPS. Spark Therapeutics’s quarterly revenue was up 14.7% on a year-over-year basis. ILLEGAL ACTIVITY WARNING: “Spark Therapeutics, Inc. Expected to Post Q1 2018 Earnings of ($1.99) Per Share (ONCE)” was published by American Banking News and is the sole property of of American Banking News. If you are reading this piece on another website, it was illegally stolen and reposted in violation of United States & international copyright and trademark law. The correct version of this piece can be viewed at https://www.americanbankingnews.com/2017/10/12/spark-therapeutics-inc-expected-to-post-q1-2018-earnings-of-1-99-per-share-once.html.

ONCE has been the subject of several other research reports. SunTrust Banks, Inc. reissued a “buy” rating and set a $95.00 price target (up previously from $85.00) on shares of Spark Therapeutics in a research report on Monday, September 25th. Jefferies Group LLC reissued a “buy” rating and set a $95.00 price target on shares of Spark Therapeutics in a research report on Tuesday. Cowen and Company reissued a “buy” rating and set a $95.00 price target on shares of Spark Therapeutics in a research report on Tuesday. Cantor Fitzgerald set a $94.00 price target on shares of Spark Therapeutics and gave the company a “buy” rating in a research report on Monday, July 17th. Finally, Goldman Sachs Group, Inc. (The) reissued a “buy” rating and set a $111.00 price target on shares of Spark Therapeutics in a research report on Friday, October 6th. Two investment analysts have rated the stock with a sell rating, two have given a hold rating and eighteen have assigned a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus target price of $88.81.

In other news, insider Katherine A. High sold 10,000 shares of the firm’s stock in a transaction on Tuesday, July 25th. The shares were sold at an average price of $72.53, for a total transaction of $725,300.00. Following the sale, the insider now directly owns 220,000 shares in the company, valued at approximately $15,956,600. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Daniel Faga sold 1,500 shares of the firm’s stock in a transaction on Tuesday, September 19th. The shares were sold at an average price of $85.00, for a total transaction of $127,500.00. Following the sale, the insider now owns 1,500 shares in the company, valued at $127,500. The disclosure for this sale can be found here. Insiders have sold a total of 1,333,195 shares of company stock worth $109,070,506 over the last 90 days. Insiders own 7.30% of the company’s stock.

Several hedge funds have recently made changes to their positions in the company. BlackRock Inc. increased its holdings in Spark Therapeutics by 11,332.0% in the 1st quarter. BlackRock Inc. now owns 1,840,214 shares of the biotechnology company’s stock valued at $98,158,000 after acquiring an additional 1,824,117 shares during the last quarter. Janus Henderson Group PLC bought a new stake in Spark Therapeutics in the 2nd quarter valued at $30,848,000. Wellington Management Group LLP increased its holdings in Spark Therapeutics by 119.5% in the 1st quarter. Wellington Management Group LLP now owns 808,782 shares of the biotechnology company’s stock valued at $43,140,000 after acquiring an additional 440,287 shares during the last quarter. Sectoral Asset Management Inc bought a new stake in Spark Therapeutics in the 2nd quarter valued at $6,052,000. Finally, Vanguard Group Inc. increased its holdings in Spark Therapeutics by 5.3% in the 2nd quarter. Vanguard Group Inc. now owns 1,924,463 shares of the biotechnology company’s stock valued at $114,968,000 after acquiring an additional 96,803 shares during the last quarter. Hedge funds and other institutional investors own 77.84% of the company’s stock.

About Spark Therapeutics

Spark Therapeutics, Inc is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical trial and a product candidate for hemophilia A, which is in a Phase I/II clinical trial.

Earnings History and Estimates for Spark Therapeutics (NASDAQ:ONCE)

Receive News & Ratings for Spark Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.